"10.1371_journal.pone.0048644","plos one","2012-11-02T00:00:00Z","Frédéric Coutant; Raul Yusef Sanchez David; Tristan Félix; Aude Boulay; Laxmee Caleechurn; Philippe Souque; Catherine Thouvenot; Catherine Bourgouin; Anne-Sophie Beignon; Pierre Charneau","Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France; Centre de Production et dInfection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France","Conceived and designed the experiments: FC CB ASB PC. Performed the experiments: FC RYSD TF AB LC PS CT ASB. Analyzed the data: FC CB ASB PC. Contributed reagents/materials/analysis tools: CB. Wrote the paper: FC CB ASB PC.","We have read the journals policy and have the following conflicts. PC is the founder of theravectys, a company whose goal is to develop a therapeutic AIDS vaccine using lentiviral vectors. FC and PC are inventors of a patent titled Lentiviral vector based immunological compounds against malaria (international patent application W02011138251 filed on April 24, 2011) and which is owned by the Institut Pasteur. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Frédéric Coutant","FC",10,TRUE,4,8,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
